Compounds > 7-13-bis(4-nitrobenzyl)-1-4-10-trioxa-7-13-diazacyclopentadecane

7-13-bis(4-nitrobenzyl)-1-4-10-trioxa-7-13-diazacyclopentadecane and Sarcoma--Ewing

7-13-bis(4-nitrobenzyl)-1-4-10-trioxa-7-13-diazacyclopentadecane has been researched along with Sarcoma--Ewing* in 1 studies

Other Studies

1 other study(ies) available for 7-13-bis(4-nitrobenzyl)-1-4-10-trioxa-7-13-diazacyclopentadecane and Sarcoma--Ewing

Article	Year
A targeted combinatorial therapy for Ewing's sarcoma. Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 37 Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. Finally, animal studies validated that ML111-NP efficiently accumulate in orthotopic EwS xenografts after intravenous injection and provide superior therapeutic outcomes in a combination with vincristine without evident toxicity. These results support the potential of the ML111-based combinatorial therapy for EwS. Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Humans; Mice; Nanoparticles; Sarcoma, Ewing; Vincristine; Xenograft Model Antitumor Assays	2021

Article

Year

A targeted combinatorial therapy for Ewing's sarcoma.

Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 37

Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. Finally, animal studies validated that ML111-NP efficiently accumulate in orthotopic EwS xenografts after intravenous injection and provide superior therapeutic outcomes in a combination with vincristine without evident toxicity. These results support the potential of the ML111-based combinatorial therapy for EwS.

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Humans; Mice; Nanoparticles; Sarcoma, Ewing; Vincristine; Xenograft Model Antitumor Assays

2021